Parise Junior Orlando, Carvalho Leda Viegas, Miguel Roberto Elias Villela, Kowalski Luiz Paulo
Department of Head and Neck Surgery, Hospital AC Camargo, São Paulo, Brazil.
Sao Paulo Med J. 2004 Nov 4;122(6):264-8. doi: 10.1590/s1516-31802004000600007. Epub 2005 Feb 2.
p53, c-erbB-2 and epidermal growth factor receptor (EGFR) are cancer-related proteins that are usually expressed in head and neck squamous cell carcinoma (SCC). Their prognostic value remains controversial.
To evaluate the prognostic impact of p53, c-erbB-2 and EGFR expression in head and neck SCC.
Prospective.
Head and Neck Surgery Department, Hospital AC Camargo, São Paulo.
Fifty-four patients were studied for p53, c-erbB-2 and EGFR expression in head and neck SCC and adjacent mucosa, via immunohistochemistry. These data were correlated with histoclinical data and survival.
There was a direct association of p53 expression in SCC and mucosa (p = 0.001); loss of c-erbB-2 expression (-) from normal mucosa to SCC (p = 0.04); lower frequency of association of c-erbB-2 (+) with EGFR (-) in SCC (p = 0.02); and a direct association of EGFR (+) expression in SCC and mitotic index (p = 0.03). The 60-month actuarial survival rates for patients presenting lymph node metastasis were higher when there was no capsule rupture by SCC (48.3%; p = 0.02), no more than one positive lymph node (52.3%; p = 0.004) or clear surgical margins (47.0%; p = 0.01), in comparison with patients presenting capsule rupture (20.2%), two or more positive lymph nodes (18.7%) or compromised surgical margins (0.0%), respectively. Patients presenting SCC p53 (+) and EGFR (-) demonstrated greater survival (75.0%; p = 0.03) than for the remaining group (33.1%). Multivariate analysis confirmed the positive impact of p53 (+) and EGFR (-) on survival (p = 0.02).
Associations were found for p53, c-erbB-2 and EGFR expression with histoclinical data and prognosis. Interestingly, these results suggest that loss of mucosal c-erbB-2 expression could be involved in SCC carcinogenesis; EGFR expression in SCC is related to tumor mitotic index; and presence of p53 with absence of EGFR expression in head and neck SCC may be a prognostic factor for survival.
Further prospective studies should be conducted to confirm the influence of p53, c-erbB-2 and EGFR on histoclinical data and prognosis.
p53、c-erbB-2和表皮生长因子受体(EGFR)是通常在头颈部鳞状细胞癌(SCC)中表达的癌症相关蛋白。它们的预后价值仍存在争议。
评估p53、c-erbB-2和EGFR表达对头颈部SCC的预后影响。
前瞻性研究。
圣保罗AC卡马戈医院头颈外科。
通过免疫组织化学研究了54例头颈部SCC及相邻黏膜中p53、c-erbB-2和EGFR的表达。这些数据与组织临床数据和生存率相关。
SCC和黏膜中p53表达呈直接关联(p = 0.001);从正常黏膜到SCC,c-erbB-2表达缺失(-)(p = 0.04);SCC中c-erbB-2(+)与EGFR(-)的关联频率较低(p = 0.02);SCC中EGFR(+)表达与有丝分裂指数呈直接关联(p = 0.03)。与出现SCC包膜破裂(20.2%)、两个或更多阳性淋巴结(18.7%)或手术切缘受累(0.0%)的患者相比,出现淋巴结转移的患者在SCC未出现包膜破裂(48.3%;p = 0.02)、阳性淋巴结不超过一个(52.3%;p = 0.004)或手术切缘清晰(47.0%;p = 0.01)时,60个月精算生存率更高。出现SCC p53(+)和EGFR(-)的患者生存率(75.0%;p = 0.03)高于其余组(33.1%)。多因素分析证实p53(+)和EGFR(-)对生存率有积极影响(p = 0.02)。
发现p53、c-erbB-2和EGFR表达与组织临床数据和预后相关。有趣的是,这些结果表明黏膜c-erbB-2表达缺失可能参与SCC的致癌过程;SCC中EGFR表达与肿瘤有丝分裂指数相关;头颈部SCC中p53存在且EGFR表达缺失可能是生存的预后因素。
应进行进一步的前瞻性研究以证实p53、c-erbB-2和EGFR对组织临床数据和预后的影响。